Risk of bleeding with the concurrent use of amiodarone and DOACs: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy · 02.05.2025 · 11 (3) · 241-250
DOI: 10.1093/ehjcvp/pvae097 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 24.12.2024. Verfasst von Faith Michael und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Health Sciences North, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1, Canada. Hauptthemen laut MEDLINE: Amiodarone, Atrial Fibrillation, Anti-Arrhythmia Agents, Hemorrhage. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims Amiodarone is frequently prescribed alongside direct oral anticoagulants (DOACs) in atrial fibrillation. There are concerns regarding drug-drug interactions (DDIs) between amiodarone and DOACs. The literature is conflicting on the clinical implications of this DDI, hence we conducted a meta-analysis to compare bleeding risk among patients receiving DOACs, with and without concurrent amiodarone. Methods and results A systematic search was conducted for studies published between 1 January 2009 and 26 June 2024 in MEDLINE via PubMed, Embase, and CENTRAL. Included studies compared major bleeding in patients on concurrent amiodarone and DOACs to those on DOACs without amiodarone. Event rates were used to calculate odds ratios (ORs), which were pooled with a random-effects model. Nine studies were identified, which included 124 813 patients on amiodarone/DOACs, and 314 074 on DOACs. The average age was 77.2 years in the amiodarone/DOAC group, compared to 74.4 years in the DOAC group (P = 0.21). Among DOAC patients, there was a statistically significant increase in major bleeding with concurrent amiodarone (OR 1.22, 95% confidence interval (CI) 1.03–1.44, P = 0.02, I2 = 88%). Intracranial bleeding rate was numerically higher in the amiodarone/DOAC group (1.0 vs. 0.4%), but the difference did not reach statistical significance (OR 2.20, 95% CI 0.53–9.06, P = 0.27, I2 = 100%). There were no significant differences in gastrointestinal bleeding (OR 1.10, 95% CI 0.98–1.23, P = 0.12, I2 = 62%) and all-cause mortality (OR 1.38, 95% CI 0.70–2.73, P = 0.35, I2 = 99%). Conclusion Concurrent use of amiodarone and DOACs was associated with an increase in major bleeding. This should be considered when co-prescribing these medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Health Sciences North, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1, Canada.
- Department of General Internal Medicine, Queen's University, Kingston, Ontario K7L 3N6, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario M5T 3M6, Canada.
- ICES, Toronto and North, Ontario M4N 3M5, Canada.
- Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, 309 E. Second St., Pomona, CA 91766-1854, USA.
- Pharmacy Department, VA Greater Los Angeles Healthcare System, CA 90073-1003, USA.
ORCID-Profile: Eugene Crystal, Jason G Andrade, Dennis T Ko, Mohammed Shurrab
Zitieren
APA
Michael, F., Quevillon, T., Maisonneuve, S., Jackevicius, C. A., Crystal, E., Parkash, R., Andrade, J. G., Healey, J. S., Ko, D. T., & Shurrab, M. (2025). Risk of bleeding with the concurrent use of amiodarone and DOACs: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 11(3), 241-250. https://doi.org/10.1093/ehjcvp/pvae097
Vancouver
Michael F, Quevillon T, Maisonneuve S, Jackevicius CA, Crystal E, Parkash R, et al. Risk of bleeding with the concurrent use of amiodarone and DOACs: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 2025;11(3):241-250. doi:10.1093/ehjcvp/pvae097
BibTeX
@article{Michael2025,
author = {Michael, Faith and Quevillon, Travis and Maisonneuve, Sabrina and Jackevicius, Cynthia A and Crystal, Eugene and Parkash, Ratika and Andrade, Jason G and Healey, Jeff S and Ko, Dennis T and Shurrab, Mohammed},
title = {Risk of bleeding with the concurrent use of amiodarone and DOACs: a systematic review and meta-analysis},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
volume = {11},
number = {3},
pages = {241--250},
doi = {10.1093/ehjcvp/pvae097}
}
EUVIMED